Previous 10 | Next 10 |
The shares of the Medpace Holdings (NASDAQ:MEDP) have reached a 52-week low on Tuesday after the contract research organization set the 2022 outlook unchanged despite its 1Q 2022 financials that stood above Street forecasts. The peers in the subsector, including ICON (ICLR), IQVIA Holdin...
Inotiv (NOTV -3.7%) has announced the acquisition of Histion, where the acquisition is a strategic element of the Co.’s expansion of its specialized pathology services. “This acquisition will also support the previously announced expansion of our surgical model and medical ...
WEST LAFAYETTE, Ind., April 25, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and d...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips This article is excerpted from Tom Yeung’s Moonshot Investor newsletter. To make sure you don’t miss any of Tom’s potential 100x picks, subscribe to his mailing list here . Insider Buying Co...
Following back-to-back intraday losses, Inotiv (NOTV +17.0%) shares have recovered sharply after the company’s Chief Executive Officer Robert Leasure and Chief Strategy Officer John Sagartz disclosed insider purchases on Thursday. According to regulatory filings, Leasure, who is also t...
Inotiv, Inc. (NOTV) Q1 2022 Earnings Conference Call February 10, 2022, 4:30 PM ET Company Participants Bob Leasure – President and Chief Executive Officer Beth Taylor – Chief Financial Officer Kalle Ahl – The Equity Group Conference Call Participants Kyle Bauser –...
Inotiv press release (NASDAQ:NOTV): Q1 GAAP EPS of -$3.93 misses by $3.89. Revenue of $84.2M (+370.4% Y/Y) beats by $11.42M. For further details see: Inotiv GAAP EPS of -$3.93 misses by $3.89, revenue of $84.2M beats by $11.42M
WEST LAFAYETTE, Ind., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”) , a leading contract research organization specializing in nonclinical and analytical drug discovery a...
Inotiv is a leading mid-market CRO offering a full suite of non-clinical services. The Company has been on an acquisition spree, latest being Envigo, upping its game to full programs. The Company's revenue has been growing steadily at a CAGR of +50% through 2021 and is expected to...
WEST LAFAYETTE, Ind., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, “We”, “Our” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and de...
News, Short Squeeze, Breakout and More Instantly...
WEST LAFAYETTE, Ind., June 10, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and rela...